EUCTR2013-004122-28-GB进行中（未招募）1 期
An investigator-initiated double-blind, parallel-group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes: the GOLMePsA study. - GOLMePsA
The Leeds Teaching Hospitals NHS Trust0 个研究点目标入组 88 人开始时间: 2015年1月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male and female patients aged =18 years at the time of signing the Informed Consent Form.
- •2.Subjects with a diagnosis of psoriatic arthritis as per the Classification for Psoriatic Arthritis (CASPAR) criteria (Appendix 4) confirmed less than 24 months prior to screening.
- •3.Subjects with active PsA defined as the presence of at least 3/68 tender and at least 3/66 swollen joints or 2 swollen and 2 tender joints plus one affected entheseal site (Achilles tendon and/or plantar fascia) at baseline.
- •4.Subjects should have one or more active inflammatory lesions (bone marrow oedema/osteitis/enthesitis or synovitis) on WB-MRI at baseline.
- •5.Are treatment naïve to DMARDs.
- •6.Are capable of understanding and signing an informed consent form.
- •7.Women of childbearing potential or men capable of fathering children must be using adequate birth control measures (eg, abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilization) during the study and for 6 months after receiving the last administration of study agent. Female subjects of childbearing potential must test negative for pregnancy. Female subjects must agree to not donate eggs (ova, oocytes) during the study and for 6 months after last dose of study agent. Male subjects must agree to not donate sperm while in the study and for 6 months after last dose of study agent.
- •8.Patients fulfilling the following TB criteria:
- •8.1.Have no history of latent or active TB prior to screening. An exception is made for subjects with a history of latent TB and documentation of having completed appropriate treatment for latent TB 3 years prior to the first administration of study agent. It is the responsibility of the investigator to verify the adequacy of previous antituberculous treatment and provide appropriate documentation.
- •8.2.Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.
- •8.3.Have had no close contact with a person with active TB or, if there has been such a contact, will be referred to a physician specializing in TB to undergo additional evaluation, and if warranted, receive appropriate treatment as if having latent TB prior to or simultaneously with the first administration of study agent.
- •8.4.Within 6 weeks prior to the administration of study agent, either have a negative QuantiFERON-TB Gold test result or have a newly identified positive QuantiFERON-TB Gold test result in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study agent.
- •8.5.In the event of 2 inderterminate QuantiFERON-TB Gold in-tube tests results, the subjects will be treated as if having latent TB prior or simultaneously with the first administration of study agent.
- •8.6.Have a chest radiograph (posterior-anterior view), read by a qualified radiologist, whose diagnostic assessment is consistent with no evidence of current active TB or old inactive TB, and taken within 12 months of the study.
- •8.7.Have a screening laboratory test result as follows:
- •8.7.1.Hb=8.5 g/dL or =5.3 mmol/L
- •8.7.2.White blood cell (WBC) count =3.5x103 cells/uL
- •8.7.3.Neutrophils =1.5 x103 cells/uL
- •8.7.4.Platelets =100x103 cells/uL
- •8.7.5.Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels not exceeding 1.5 times the upper limit of normal (UKN) for the central laboratory conducting the test.
排除标准
- •1.Received previous treatment with any DMARDs.
- •2.Received previous treatment with Golimumab or other tumour necrosis factor inhibitor (TNFi) or other biologic drugs.
- •3.Any chronic inflammatory arthritis diagnosed before 16 years old.
研究者
相似试验
招募中
1 期
Evaluation of safety and effectiveness of a nebulised phage cocktail in patients with chronic rhinosinusitis (CRS)chronic rhinosinusitisACTRN12623000542695Central Adelaide Local Health Network66
进行中（未招募）
1 期
A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambulant subjects with Duchenne muscular dystrophyMedDRA version: 14.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2010-018412-32-BEGlaxoSmithKline Research and Development LTD54
进行中（未招募）
不适用
A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambulant subjects with Duchenne muscular dystrophyDuchenne Muscular DystrophyMedDRA version: 14.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-018412-32-GBGlaxoSmithKline Research and Development LTD54
进行中（未招募）
1 期
A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambulant subjects with Duchenne muscular dystrophyMedDRA version: 12.1 Level: LLT Classification code 10013801 Term: Duchenne muscular dystrophyDuchenne Muscular DystrophyEUCTR2010-018412-32-FRGlaxoSmithKline Research and Development LTD53
进行中（未招募）
不适用
A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambulant subjects with Duchenne muscular dystrophyDuchenne Muscular DystrophyMedDRA version: 12.1Level: LLTClassification code 10013801Term: Duchenne muscular dystrophyEUCTR2010-018412-32-NLGlaxoSmithKline Research and Development LTD54